XenoPort, Reckitt Benckiser in licensing deal for alcoholism treatment


XenoPort (XNPT) has signed a licensing deal for Reckitt Benckiser (RBGLY) to develop XenoPort's Arbaclofen Placarbil treatment for alcoholism.

XenoPort will receive $20M upfront, $5M after certain technology and materials have been transferred, up to $70M in development and regulatory milestones, and $50M for commercial achievements.

Reckitt Benckiser will also start Phase IIb trials of Arbaclofen Placarbil. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs